Series A · Biotech · London, United Kingdom · Founded 2016 · 50–60 employees
Engitix is a pioneering biotech company founded in 2016 that develops transformative therapies for cancer and fibrosis by targeting the extracellular matrix (ECM). The company has built one of the world's largest proprietary ECM bioarchives and uses AI/ML methods to decode matrix biology for drug discovery. Recently secured €21 million Series A extension in January 2026, bringing total funding to over $85 million. Has strategic partnerships with major pharma companies including Takeda Pharmaceuticals and Dompé Farmaceutici, validating their platform approach.